{"id":"clm_1515428319F6","entity":"regeneron-pharmaceuticals","predicate":"total_equity","value":"19,914,700,000 United States dollar","value_json":{"fp":"Q1","fy":2022,"accn":"0001804220-22-000015","form":"10-Q","filed":"2022-05-04","period":"Q1 FY2022","concept":"us-gaap:StockholdersEquity"},"valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 19,914,700,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_1515428319F6, https://asof.is/claim/clm_1515428319F6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.","url":"https://asof.is/claim/clm_1515428319F6","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5C8D7A0356F3","supersedes":["clm_193A31C30AA8"],"first_seen_at":"2026-11-08T17:08:55.512322+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-04"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}